Bladder control issues affect millions of people worldwide, impacting daily activities and quality of life. While common, these conditions remain treatable through various medical interventions, ...
NCCN now includes Anktiva plus BCG for BCG-unresponsive papillary-only NMIBC, acknowledging an unmet need in patients without ...
After matching, standardized mean differences were <0.1 for all key covariates. NAI + BCG showed improved outcomes versus other bladder sparing therapies in the d-uo cohort, including increased ...
A new study using functional magnetic resonance imaging (fMRI) reveals the neural mechanisms that contribute to urinary incontinence, a common condition affecting stroke survivors that has a ...
ImmunityBio’s sBLA targets BCG-unresponsive papillary NMIBC without CIS, complementing the existing U.S. approval for CIS with or without papillary tumors. FDA interactions centered on updated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results